

# Mohamed Shanavas

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/745475/publications.pdf>

Version: 2024-02-01

13  
papers

209  
citations

1478505

6  
h-index

1199594

12  
g-index

13  
all docs

13  
docs citations

13  
times ranked

502  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma. Blood Advances, 2021, 5, 2644-2649.	5.2	7
2	Intratumoral Tâ€cell receptor repertoire is predictive of interim PET scan results in patients with diffuse large Bâ€cell lymphoma treated with rituximab/cyclophosphamide/doxorubicin/prednisolone/vincristine (Râ€CHOP) chemoimmunotherapy. Clinical and Translational Immunology, 2021, 10, e1351.	3.8	1
3	Capturing the Lived Experiences of Women with Lymphoma in Pregnancy: An Australasian Lymphoma Alliance Study. Blood, 2021, 138, 4099-4099.	1.4	1
4	Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance. Blood, 2021, 138, 882-882.	1.4	3
5	The Tumor Microenvironment Is Independently Prognostic of Conventional and Clinicogenetic Risk Models in Follicular Lymphoma. Blood, 2017, 130, 728-728.	1.4	2
6	The T-Cell Receptor Repertoire Predicts Interim-PET in Patients with DLBCL Treated with R-CHOP: An Observational Study from a Prospective Clinical Trial. Blood, 2017, 130, 825-825.	1.4	0
7	Outcomes of Allogeneic Hematopoietic Cell Transplantation inâ€Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biology of Blood and Marrow Transplantation, 2016, 22, 432-440.	2.0	127
8	Effect of Red Blood Cell Transfusion Dependence on the Natural History of Myeloproliferative Neoplasm-Associated Myelofibrosis. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, e151-e156.	0.4	11
9	Mycophenolateâ€based graft versus host disease prophylaxis is not inferior to methotrexate in myeloablativeâ€related donor stem cell transplantation. American Journal of Hematology, 2015, 90, 392-399.	4.1	17
10	Molecular relapse after allogeneic hematopoietic cell transplant for chronic myeloid leukemia: some long-term survivors appear to tolerate even lack of major molecular response. Leukemia and Lymphoma, 2014, 55, 2398-2401.	1.3	1
11	A Comparison of Long-Term Outcomes of Donor Lymphocyte Infusions and Tyrosine Kinase Inhibitors in Patients With Relapsed CML After Allogeneic Hematopoietic Cell Transplantation. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, 87-92.	0.4	21
12	Controversies and dilemmas in allogeneic transplantation for myelofibrosis. Best Practice and Research in Clinical Haematology, 2014, 27, 165-174.	1.7	3
13	Incidence, Risk Factors, and Long-Term Outcomes of Sclerotic Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 1751-1757.	2.0	15